Gilead Financial Statements From 2010 to 2024

GILD Stock  USD 66.76  0.60  0.91%   
Gilead Sciences financial statements provide useful quarterly and yearly information to potential Gilead Sciences investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Gilead Sciences financial statements helps investors assess Gilead Sciences' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Gilead Sciences' valuation are summarized below:
Gross Profit
21.6 B
Profit Margin
0.2089
Market Capitalization
83.9 B
Enterprise Value Revenue
3.7839
Revenue
27.1 B
There are over one hundred nineteen available fundamental trends for Gilead Sciences, which can be analyzed over time and compared to other ratios. Investors should ensure to confirm all of Gilead Sciences' regular performance against the performance from 2010 to 2024 to make sure the company is sustainable down the road. The current year's Market Cap is expected to grow to about 108.5 B. The current year's Enterprise Value is expected to grow to about 106.5 B

Gilead Sciences Total Revenue

28.47 Billion

Check Gilead Sciences financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Gilead main balance sheet or income statement drivers, such as Interest Expense of 534.5 M, Total Revenue of 28.5 B or Gross Profit of 28.5 B, as well as many exotic indicators such as Price To Sales Ratio of 3.54, Dividend Yield of 0.0485 or PTB Ratio of 7.85. Gilead financial statements analysis is a perfect complement when working with Gilead Sciences Valuation or Volatility modules.
  
This module can also supplement Gilead Sciences' financial leverage analysis and stock options assessment as well as various Gilead Sciences Technical models . Check out the analysis of Gilead Sciences Correlation against competitors.
For information on how to trade Gilead Stock refer to our How to Trade Gilead Stock guide.

Gilead Sciences Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets65.2 B62.1 B48.5 B
Slightly volatile
Short and Long Term Debt Total26.2 B25 B17.5 B
Slightly volatile
Other Current Liabilities11.8 B11.3 B6.9 B
Slightly volatile
Total Current Liabilities11.8 B11.3 B8.5 B
Slightly volatile
Total Stockholder Equity23.9 B22.7 B17 B
Slightly volatile
Property Plant And Equipment Net5.6 B5.3 B3.2 B
Slightly volatile
Accounts Payable518.2 M550 M864.5 M
Pretty Stable
Cash3.8 B6.1 B7.2 B
Very volatile
Non Current Assets Total48 B45.7 B28.2 B
Slightly volatile
Cash And Short Term Investments7.5 B8.4 B14.6 B
Very volatile
Common Stock Shares Outstanding1.5 B1.3 B1.3 B
Very volatile
Liabilities And Stockholders Equity65.2 B62.1 B48.5 B
Slightly volatile
Non Current Liabilities Total29.5 B28.1 B23 B
Slightly volatile
Other Current Assets1.3 B2.4 B1.8 B
Pretty Stable
Total Liabilities41.3 B39.4 B31.5 B
Slightly volatile
Total Current Assets10.8 B16.5 B19.9 B
Pretty Stable
Net Receivables2.4 B4.7 B3.5 B
Slightly volatile
Property Plant And Equipment Gross8.2 B7.8 B3.8 B
Slightly volatile
Short Term Investments1.1 B1.2 B3.6 B
Pretty Stable
Inventory3.5 B3.4 BB
Slightly volatile
Other Liabilities8.8 B8.4 B6.4 B
Slightly volatile
Other Assets1.1 M1.1 M1.8 B
Pretty Stable
Long Term Debt12.2 B23.2 B17.9 B
Slightly volatile
Common Stock Total Equity892.4 K1.1 MM
Pretty Stable
Capital Stock901 K1.1 MM
Pretty Stable
Common Stock901 K1.1 MM
Pretty Stable
Property Plant Equipment6.6 B6.3 B3.3 B
Slightly volatile
Good Will10 B9.6 B4.3 B
Slightly volatile
Long Term Debt Total19.7 B26.4 B19.2 B
Slightly volatile
Capital Surpluse2.7 BB3.3 B
Very volatile
Long Term Investments1.1 B1.2 B3.8 B
Pretty Stable
Non Current Liabilities Other1.2 B1.3 B3.4 B
Slightly volatile
Deferred Long Term Asset Charges234.5 M462.3 M312.2 M
Slightly volatile
Intangible Assets16.7 B26.5 B16.2 B
Slightly volatile
Warrants1.7 M1.8 M6.3 M
Slightly volatile
Short and Long Term Debt3.5 B1.8 B3.3 B
Very volatile
Net Invested Capital39 B47.8 B50.6 B
Slightly volatile
Net Working Capital9.5 B4.8 B15.6 B
Slightly volatile

Gilead Sciences Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Interest Expense534.5 M944 M701.8 M
Slightly volatile
Total Revenue28.5 B27.1 B21.5 B
Slightly volatile
Gross Profit28.5 B27.1 B18.2 B
Slightly volatile
Other Operating Expenses20.5 B19.5 B12.1 B
Slightly volatile
Total Operating Expenses12.4 B11.8 B7.7 B
Slightly volatile
Research DevelopmentB5.7 B4.1 B
Slightly volatile
Selling General Administrative6.8 B6.5 B3.5 B
Slightly volatile
Net Income Applicable To Common Shares4.9 B5.3 B5.9 B
Very volatile
Net Income From Continuing Ops6.6 B5.8 B6.2 B
Very volatile
Interest Income194.1 M204.3 M506.6 M
Slightly volatile
Non Recurring4.4 B4.2 B1.8 B
Slightly volatile
Reconciled Depreciation1.9 B2.5 B1.5 B
Slightly volatile
Selling And Marketing Expenses618.4 M700.2 M764.4 M
Slightly volatile

Gilead Sciences Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Begin Period Cash Flow3.5 B5.4 B6.9 B
Pretty Stable
Depreciation2.8 B2.7 B1.3 B
Slightly volatile
Capital Expenditures614.2 M585 M551.2 M
Slightly volatile
End Period Cash Flow3.7 B6.1 B7.2 B
Very volatile
Stock Based Compensation422.3 M766 M466.5 M
Slightly volatile
Issuance Of Capital Stock295.9 M382 M281.5 M
Very volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio3.543.728414.0019
Slightly volatile
Dividend Yield0.04850.03770.0406
Pretty Stable
PTB Ratio7.854.44426.5734
Slightly volatile
Days Sales Outstanding59.5962.7268854
Slightly volatile
Book Value Per Share19.1418.228412.8005
Slightly volatile
Invested Capital1.151.09841.0639
Slightly volatile
Stock Based Compensation To Revenue0.04150.02820.0226
Slightly volatile
PB Ratio7.854.44426.5734
Slightly volatile
EV To Sales4.24.425513.9079
Slightly volatile
Inventory Turnover1.521.7732.3679
Pretty Stable
Days Of Inventory On Hand270206200
Slightly volatile
Sales General And Administrative To Revenue0.310.210.208
Pretty Stable
Research And Ddevelopement To Revenue0.20.21090.6002
Slightly volatile
Cash Per Share3.085.82058.1005
Pretty Stable
Interest Coverage11.549.923713.5745
Slightly volatile
Payout Ratio0.640.67243.1524
Pretty Stable
Income Quality1.361.42637.4515
Pretty Stable
Current Ratio1.391.45872.7572
Slightly volatile
Receivables Turnover3.95.81895.2754
Slightly volatile
Graham Number45.3143.147733.2301
Slightly volatile
Shareholders Equity Per Share19.1418.228412.8005
Slightly volatile
Debt To Equity1.151.09841.0639
Slightly volatile
Revenue Per Share22.8121.727616.1898
Slightly volatile
Debt To Assets0.420.40220.3759
Slightly volatile
Operating Cycle255269K
Slightly volatile
Price Book Value Ratio7.854.44426.5734
Slightly volatile
Dividend Payout Ratio0.640.67243.1524
Pretty Stable
Ebt Per Ebit0.680.73220.8813
Slightly volatile
Company Equity Multiplier1.582.73092.6071
Slightly volatile
Long Term Debt To Capitalization0.530.50480.4745
Slightly volatile
Total Debt To Capitalization0.550.52340.4895
Slightly volatile
Debt Equity Ratio1.151.09841.0639
Slightly volatile
Quick Ratio1.01.05712.1361
Slightly volatile
Dividend Paid And Capex Coverage Ratio2.752.48334.6853
Pretty Stable
Net Income Per E B T0.940.82590.7417
Pretty Stable
Cash Ratio0.510.53951.3626
Slightly volatile
Cash Conversion Cycle223235148
Slightly volatile
Days Of Inventory Outstanding270206200
Slightly volatile
Days Of Sales Outstanding59.5962.7268854
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.120.92690.9576
Very volatile
Price To Book Ratio7.854.44426.5734
Slightly volatile
Fixed Asset Turnover5.025.09997.5727
Slightly volatile
Debt Ratio0.420.40220.3759
Slightly volatile
Price Sales Ratio3.543.728414.0019
Slightly volatile
Asset Turnover0.320.43650.4306
Pretty Stable
Gross Profit Margin1.070.77990.8705
Pretty Stable
Price Fair Value7.854.44426.5734
Slightly volatile

Gilead Sciences Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap108.5 B103.3 B98.1 B
Slightly volatile
Enterprise Value106.5 B101.5 B97.3 B
Slightly volatile

Gilead Fundamental Market Drivers

Forward Price Earnings9.6432
Cash And Short Term Investments8.4 B

Gilead Upcoming Events

6th of February 2024
Upcoming Quarterly Report
View
25th of April 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
6th of February 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Gilead Sciences Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Gilead Sciences income statement, its balance sheet, and the statement of cash flows. Gilead Sciences investors use historical funamental indicators, such as Gilead Sciences's revenue or net income, to determine how well the company is positioned to perform in the future. Although Gilead Sciences investors may use each financial statement separately, they are all related. The changes in Gilead Sciences's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Gilead Sciences's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Gilead Sciences Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Gilead Sciences. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue-2.1 B-2 B
Total Revenue27.1 B28.5 B
Cost Of Revenue5.8 B6.1 B
Stock Based Compensation To Revenue 0.03  0.04 
Sales General And Administrative To Revenue 0.21  0.31 
Research And Ddevelopement To Revenue 0.21  0.20 
Capex To Revenue(0.02)(0.02)
Revenue Per Share 21.73  22.81 
Ebit Per Revenue 0.35  0.36 

Gilead Sciences Investors Sentiment

The influence of Gilead Sciences' investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Gilead. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock market does not have solid backing from leading economists and market statisticians.
Investor biases related to Gilead Sciences' public news can be used to forecast risks associated with an investment in Gilead. The trend in average sentiment can be used to explain how an investor holding Gilead can time the market purely based on public headlines and social activities around Gilead Sciences. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Gilead Sciences' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Gilead Sciences' and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average Gilead Sciences' news discussions. The higher the estimated score, the more favorable is the investor's outlook on Gilead Sciences.

Gilead Sciences Implied Volatility

    
  62.11  
Gilead Sciences' implied volatility exposes the market's sentiment of Gilead Sciences stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if Gilead Sciences' implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that Gilead Sciences stock will not fluctuate a lot when Gilead Sciences' options are near their expiration.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Gilead Sciences in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Gilead Sciences' short interest history, or implied volatility extrapolated from Gilead Sciences options trading.

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether Gilead Sciences is a strong investment it is important to analyze Gilead Sciences' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Gilead Sciences' future performance. For an informed investment choice regarding Gilead Stock, refer to the following important reports:

Complementary Tools for Gilead Stock analysis

When running Gilead Sciences' price analysis, check to measure Gilead Sciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Gilead Sciences is operating at the current time. Most of Gilead Sciences' value examination focuses on studying past and present price action to predict the probability of Gilead Sciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Gilead Sciences' price. Additionally, you may evaluate how the addition of Gilead Sciences to your portfolios can decrease your overall portfolio volatility.
Equity Valuation
Check real value of public entities based on technical and fundamental data
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
ETFs
Find actively traded Exchange Traded Funds (ETF) from around the world
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Analyst Advice
Analyst recommendations and target price estimates broken down by several categories
Sign In To Macroaxis
Sign in to explore Macroaxis' wealth optimization platform and fintech modules
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
Is Gilead Sciences' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Gilead Sciences. If investors know Gilead will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Gilead Sciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.13)
Dividend Share
3
Earnings Share
4.5
Revenue Per Share
21.728
Quarterly Revenue Growth
(0.04)
The market value of Gilead Sciences is measured differently than its book value, which is the value of Gilead that is recorded on the company's balance sheet. Investors also form their own opinion of Gilead Sciences' value that differs from its market value or its book value, called intrinsic value, which is Gilead Sciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Gilead Sciences' market value can be influenced by many factors that don't directly affect Gilead Sciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Gilead Sciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Gilead Sciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Gilead Sciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.